Samrat Pharmachem manufactures pharmaceutical chemicals and iodine-based intermediates used in industries such as healthcare, agrochemicals, and textiles. The company earns revenue by producing these specialty chemicals at its Gujarat facilities for both domestic Indian and international markets.
The company operates in a highly competitive commodity-like specialty chemical space with thin net margins averaging 2.4%. While it claims a strong position in iodine derivatives, the lack of durable pricing power is evidenced by a sharp drop in EBITDA and net profit in FY24 despite stable revenue, indicating an inability to pass on cost fluctuations.
Management maintains a conservative balance sheet with low debt, but reinvestment has yielded poor results recently, with EPS declining at a 2% CAGR over the period. Dividends are paid but represent a small fraction of historical earnings, and cash conversion is weak at 0.32.
The investment collapsed as the company's razor-thin margins, already evidenced by a drop from 5.35% to 0.77%, finally evaporated under the weight of commodity iodine price volatility. Management's inability to pass on costs, combined with a lack of pricing power, led to persistent net losses. The aging leadership failed to navigate a shifting regulatory landscape, and the poor cash conversion (0.32) eventually starved the business of the liquidity needed to modernize, turning a low-debt balance sheet into a trap of stagnant, unproductive assets.
RichFakir rates Samrat Pharmachem Ltd's business quality as poor — 32/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Samrat Pharmachem Ltd is trading about 19% above our estimate of fair value; we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Samrat Pharmachem Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Samrat Pharmachem Ltd's fair value is about ₹242 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →